



COLORADO

Department of Health Care
Policy & Financing

**AGENDA: DUR BOARD MEETING
Colorado Medicaid DUR
Department of Health Care Policy and Financing**

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

May 24, 2016

6:00 p.m. Closed Executive Session for Board Members

7:00 p.m. – 9:00 p.m. Open Session

DUR BOARD MEMBERS and CO DUR MEMBERS

LeWayne Garrison, PharmD
Karen Weber, DO
Sheila Botts, PharmD
Kerstin Froyd, MD
James Regan, MD
Pam Reiter, PharmD
Mark Boesen,

Robert Lodge, PharmD
Robert L Page, PharmD, MSPH
(CO DUR)
Nila Mahyari, PharmD (CO DUR)
Jon Campbell, PhD (CO DUR)
Gina Moore, PharmD

1. Roll Call

2. Approval of the minutes from the February 17, 2016 meeting

3. Rules

- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.



4. Executive Session (Closed)

- Approval of the minutes from the previous meeting
- Review Retro-DUR reports
- New R-DUR process and feedback
- Quarterly Drug Utilization Reports
- Module outlook summary
- FDA updates

5. Open Session

A. Unfinished Business and General Orders

Update on the following (update from last meeting, no discussion):

- Alzheimer's agents
- Atypical Antipsychotics
- Growth Hormones
- Leukotriene Modifiers
- MS Agents
- Intranasal corticosteroids
- Insulin
- Ophthalmic allergy products
- Sedative/Hypnotics
- Statins and Statin combinations

B. New Business

Proposed Criteria for current PDL:

- Antihistamine and combinations
- Angiotensin Receptor Blockers and combinations
- Renin Inhibitor and combinations
- Fibromyalgia agents
- Long-Acting Oral Opioids
- Inhaled Anticholinergics and combinations
- Inhaled Long-Acting Beta Agonists
- Inhaled Corticosteroids and combinations
- Skeletal Muscle Relaxants
- Testosterone Products
- Topical Immunomodulators



Proposed Criteria for Other Agents:

- Onfi (clobazam) criteria update
- Taltz (ixekizumab) criteria
- Fentanyl products criteria

6. Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or robert.lodge@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

